AAIC 2026 showcased remarkable advances in neuroimaging and biomarker technologies for Alzheimer's disease (AD) diagnosis, staging, and treatment monitoring. These developments represent a paradigm shift toward minimally invasive, highly specific diagnostic tools that will transform clinical practice.
The conference highlighted three major thrust areas:
...
Neuroimaging and Biomarker Advances at AAIC 2026
AAIC 2026 showcased remarkable advances in neuroimaging and biomarker technologies for Alzheimer's disease (AD) diagnosis, staging, and treatment monitoring. These developments represent a paradigm shift toward minimally invasive, highly specific diagnostic tools that will transform clinical practice.
Executive Summary
Mermaid diagram (expand to render)
The conference highlighted three major thrust areas:
Next-generation PET tracers — improved tau, amyloid, and novel targets
Blood-based biomarkers — p-Tau217 leading the clinical translation
Integrated biomarker panels — AT(N) framework expansion with blood markers
PET Neuroimaging Advances
Tau PET Imaging
Second-generation tau PET tracers demonstrated improved specificity and clinical utility[@fleisher2024]:
| Advance | Clinical Impact | |---|---| | Reduced off-target binding | More accurate regional quantification | | Broader disease applicability | PART and CTE imaging now feasible | | Simplified quantification | Clinical implementation simplified |
Key tracers:
[^18F]Flortaucipir (Tauvid) — FDA-approved for tau imaging
Next-generation tracers in development
Amyloid PET Innovations
Novel amyloid PET tracers offer significant advantages[@rowe2023]:
Faster kinetics: Same-day imaging protocols
Improved signal-to-noise: Better signal clarity
Reduced non-specific binding: More accurate quantification
Standardization:
Centiloid scale adoption across studies
Harmonized SUVr methods
Longitudinal change thresholds
Novel PET Targets
Synaptic Imaging
[^11C]UCB-J SV2A PET enables visualization of synaptic density[@finnema2020]:
Direct measurement of synaptic loss in AD
Correlation with cognitive performance
Potential for treatment monitoring
Neuroinflammation
Third-generation TSPO tracers and P2X7 imaging:
Reduced inter-individual variability
Targeted microglial activation assessment
Correlation with disease progression
MRI Advances
Quantitative MRI Techniques
Advanced MRI methods for clinical implementation[@jack2023]:
[Fleisher AS, et al, Tau PET imaging: optimizing detection and quantification (2024)](https://pubmed.ncbi.nlm.nih.gov/38942015/)
[Rowe CC, et al, Amyloid PET imaging: new tracers and clinical applications (2023)](https://pubmed.ncbi.nlm.nih.gov/36738452/)
[Palmqvist S, et al, Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38597015/)
[Karikari TK, et al, Blood phospho-tau181 as a biomarker for Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35292921/)
[Ashton NJ, et al, p-Tau231 as an early marker of Alzheimer's disease pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35130406/)
[Jack CR Jr, et al, MRI-based Alzheimer's disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37940918/)
[Finnema SJ, et al, Imaging synaptic density in Alzheimer's disease with SV2A PET (2020)](https://pubmed.ncbi.nlm.nih.gov/32428579/)